ASH 2021 | Assessment of MRD using hsFCM in the Phase III GAIA (CLL13) trial
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares some findings from the post-hoc analysis of minimal residual disease (MRD) using high-sensitivity flow cytometry (hsFCM) in the Phase III GAIA (CLL13) Trial (NCT02950051). In this video, Dr Eichhorst summarizes findings from this analysis, explaining in detail the different levels of MRD that were detected using hsFCM in the various venetoclax-based treatment combinations compared to chemoimmunotherapy. Based on this analysis, hsFCM improves detection of low levels of MRD and can detect past the conventional level of 10-4, which has promising implications for the future of chronic lymphocytic leukemia (CLL). This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
